Jürgen Wolf
TH Köln - University of Applied Sciences · 460 works · 29,156 citations · h-index 73
Top works
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
- Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
- Comprehensive genomic profiles of small cell lung cancer
- Sotorasib for Lung Cancers with KRAS p.G12C Mutation
- Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
- Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions
- Thoracic positron emission tomography using18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease
- Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
- Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer
- Involved-Field Radiotherapy Is Equally Effective and Less Toxic Compared With Extended-Field Radiotherapy After Four Cycles of Chemotherapy in Patients With Early-Stage Unfavorable Hodgkin’s Lymphoma: Results of the HD8 Trial of the German Hodgkin’s Lymphoma Study Group
- Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas
- Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
- Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort
- Vemurafenib for BRAF V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis
- Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer
- Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
- PD-L1 expression in small cell neuroendocrine carcinomas
- Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials